Join Karen Chagin, MD, SVP of Early-Stage Development, as she explores the challenges faced in the development of early-stage T-cell therapies. #EarlyStageDevelopment #CancerResearch https://bit.ly/4aQlIhh
Adaptimmune’s Post
More Relevant Posts
-
Exciting developments in #CLL treatment! 🌟 Recent approvals for innovative therapies like obinatuzumab and the first CAR T cell product in CLL targeting CD 19 are paving the way for improved patient care. Learn more about the evolving clinical presentation of CLL and the importance of #biomarker testing in guiding treatment decisions. #CancerResearch #MedicalInnovations #CEC #MedEd #FoamEd
-
The phase 3 RATIONALE-312 study aimed to evaluate the efficacy & safety of tislelizumab + chemotherapy as first-line treatment for ES-SCLC, which exhibited statistically significant clinical benefit & manageable safety compared w placebo + chemotherapy. https://bit.ly/4akAXPN #LCSM
-
-
In this systematic review and network meta-analysis of 27 randomized clinical trials (including a total of 13 413 individuals), the pCR rates achieved with total neoadjuvant therapy regimens outperformed standard long-course chemoradiotherapy, with long-course chemoradiotherapy plus consolidation chemotherapy showing the greatest effect estimate.
-
TODAY! Attend this live webinar on Paroxysmal Nocturnal Hemoglobinuria! The number of #PNH therapies has doubled, and you will hear about them from expert hematologists. RSVP: https://bit.ly/3YIqCuw #ParoxysmalNocturnalHemoglobinuria
-
-
Does #durvalumab in combination with #tremelimumab offer more benefit for patients with #hepatocellularcarcinoma than durvalumab alone? Learn how the combination affects OS rates:
-
There’s a lot to think about when developing new cell therapies and many challenges to face. To ensure success, you must consider patient selection, their response to treatment, and drug product monitoring — to name a few. By partnering with us, you can quickly get the data you need to drive your program forward. 🤝 Learn more about our cell therapy services here: https://bit.ly/476hVKV #PrecisionMedicine #Biomarkers #ClincialTrials
-
There’s a lot to think about when developing new cell therapies and many challenges to face. To ensure success, you must consider patient selection, their response to treatment, and drug product monitoring — to name a few. By partnering with us, you can quickly get the data you need to drive your program forward. 🤝 Learn more about our cell therapy services here: https://bit.ly/476hVKV #PrecisionMedicine #Biomarkers #ClincialTrials
-
Potential new mesothelioma drug extends survival. Integration of Pegargiminase with initial chemotherapy treatments could enhance the therapeutic results in patients suffering from nonepithelioid pleural mesothelioma, targeting to improve patient outcomes.#MesotheliomaAdvancements https://buff.ly/42Z3ZSN
-
-
There’s a lot to think about when developing new cell therapies and many challenges to face. To ensure success, you must consider patient selection, their response to treatment, and drug product monitoring — to name a few. By partnering with us, you can quickly get the data you need to drive your program forward. 🤝 Learn more about our cell therapy services here: https://bit.ly/476hVKV #PrecisionMedicine #Biomarkers #ClincialTrials
-
Potential new mesothelioma drug extends survival. Integration of Pegargiminase with initial chemotherapy treatments could enhance the therapeutic results in patients suffering from nonepithelioid pleural mesothelioma, targeting to improve patient outcomes.#MesotheliomaAdvancements https://buff.ly/42Z3ZSN
-
So true and so difficult.